The FDA’s recent approval of OZEMPIC highlights the expanding use of GLP-1 drugs beyond diabetes and weight management. Novo Nordisk’s blockbuster medication has gained another label expansion, now ...

After its potential kidney disease drug went down in flames late last year, Novo Nordisk is pinning the blame on alleged fraudulent claims by the drug’s original maker. | After its potential kidney ...

EXTON, PA, Feb. 05, 2025 (GLOBE NEWSWIRE) -- As chronic kidney disease (CKD ... the FDA’s recent label expansion of Novo Nordisk’s Ozempic® to include CKD benefits, reinforcing the drug ...

Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal.

Novo Nordisk launched "My Ozempic® Era" today, a national campaign which spotlights the longstanding Ozempic® patient ...

Ozempic was also FDA-approved to reduce the risk of cardiovascular death and worsening kidney disease in adults living with chronic kidney disease and type 2 diabetes. According to Novo Nordisk ...

Ozempic has been approved to reduce the risk of worsening kidney disease and cardiovascular death in adults with Type 2 diabetes and chronic kidney disease. Walgreens’ three core segments—U.S ...

Novo Nordisk responded to ... adults with T2D and established CV disease, and to reduce the sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, and CV death in ...

Martin Holst Lange, Executive Vice President, Development, Novo Nordisk, highlighted during the press briefing that their ...

NovoCare Pharmacy will provide all dose strengths of Wegovy at a reduced cost of $499 per month for cash-paying patients without insurance.

New York, USA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Novo Nordisk's OZEMPIC Approval Heat Up the Chronic Kidney disease Therapeutic market | DelveInsight The FDA's recent approval of OZEMPIC ...